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are requested. We have studied biomarkers that may differentiate between active and
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therapy.
Methods: Thirty-eight plasma cytokines, assessed by multiplex and enzyme immunoassays,
were analyzed in patients with active TB before and during 24 weeks of anti-TB chemo-
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382 I. Wergeland et al.Results: Plasma levels of the CXC chemokine IP-10 and soluble TNF receptor type 2 (sTNFr2)
significantly differentiated active TB from the LTBI group, irrespective of HIV status. In the
HIV-infected group the sensitivity and specificity was 100% for IP-10 with a cut-off of
2547 pg/mL. Plasma IP-10 declined gradually during anti-TB chemotherapy (12e24 weeks,
pZ 0.002) to a level comparable to LTBI and QFT negative control groups. sTNFr2 fluctuated
throughout therapy, but was decreased after 12e24 weeks (p Z 0.006).
Conclusions: IP-10 distinguished with high accuracy active TB from LTBI irrespective of HIV
infection and declined during anti-TB chemotherapy. Plasma IP-10 may serve as a diagnostic
biomarker to differentiate between the stages of TB infection and for monitoring therapy ef-
ficacy.
ª 2015 The Authors. Published by Elsevier Ltd on behalf of the The British Infection
Association. This is an open access article under the CC BY-NC-SA license (http://
creativecommons.org/licenses/by-nc-sa/4.0/).Introduction
Tuberculosis (TB) is a major global health problem, espe-
cially in the developing world. The World Health Organiza-
tion estimates that one third of the world’s population has
latent TB infection (LTBI), and that there were 9.0 million
incident active TB cases and 1.5 million deaths caused by
TB in 2013.1 Human immunodeficiency virus (HIV) infection
is globally the major risk factor contributing to the resur-
gence of TB,2 and the emergence of multi- and extensively
drug resistant (MDR and XDR) strains of Mycobacterium
tuberculosis (Mtb) have further aggravated the situation.1
Strategies for TB control aim to reduce transmission by
identification and treatment of infectious cases as well as
to reduce development of active disease by offering pre-
ventive therapy to individuals with LTBI. However, there is
shortage of reliable and rapid diagnostic tools that can
identify and discriminate between latent and active TB,
and predict therapy responses.3,4 The currently available
tests for diagnosing LTBI are the century old tuberculin
skin test (TST) and the more recent interferon gamma
(IFN-g)-release assays (IGRAs). The IGRAs offer better spec-
ificity compared to the TST, but both tests have suboptimal
sensitivity in HIV co-infected individuals, and cannot distin-
guish between the various stages of TB infection or be used
for evaluation of treatment efficacy.3,5 Sputum culture con-
version within the first 2 months of anti-TB chemotherapy
could serve as a predictor of a favorable outcome,6,7 but
may also fail as predictive marker of cure in individual pa-
tients,8,9 and are not applicable in extra-pulmonary and
culture negative TB infection. Further, the need of alterna-
tive tools for monitoring treatment efficacy and for identi-
fying patients at high risk of relapse is emphasized by the
challenges of MDR- and XDR-TB cases, which require long
lasting treatment with potentially inefficient and toxic
drugs. Tools for monitoring treatment are also essential
for accelerating drug development.
Alternative biomarkers have been sought to improve
immune diagnosis of TB and monitoring of treatment
efficacy. Various single or combinations of markers have
been suggested to differentiate between latent and active
TB infection.10e15 However, a recent review concludes that
there is no clear pattern of markers able to differentiate
between the various TB infection stages.16 Tests based on
IFN-g -inducible Protein 10 (IP-10)/CXCL10, one of the
most studied surrogate biomarkers, perform comparablyto the QuantiFERON-TB (QFT) in most patient groups,17
but may increase the diagnostic accuracy of TB infection
in both HIV-infected individuals18e20 and children.21e24 It
has also been suggested that IP-10 can be used to monitor
treatment efficacy,14,25e29 but longitudinal studies per-
formed on diverse patient populations are limited.
The aims of this study were to examine the potential of
38 selected cytokines, including interleukins, chemokines
and growth factors to differentiate between the stages of
TB infection as well examine the influence of HIV co-
infection and the changes in these markers during anti-TB
chemotherapy. Plasma IP-10 appeared to be the most
consistent of the biomarkers studied, as it was the only
marker that significantly differentiated active TB from both
the LTBI and QFT negative control groups irrespective of
HIV status and also gradually and significantly declined
during anti-TB chemotherapy.Materials and methods
Study participants and sample collection
The study population was included from clinical studies
performed at three different hospitals in Norway in the
period 2006e2012; Haukeland University Hospital,30,31
University Hospital of Northern Norway31 and Oslo Univer-
sity Hospital.32 The study participants were recruited
from patients diagnosed with active TB and from individuals
referred to the hospitals for medical evaluation of LTBI
based on a positive TST and/or exposure of TB.30,32 HIV-
infected individuals were recruited from outpatient infec-
tious disease clinics.31 QFT negative/HIV-uninfected indi-
viduals from age-matched employees with no known
exposure to TB served as controls.
Thoracic X-ray and clinical examination were performed
in all participants and an induced sputum sample and/or
biopsy was obtained for acid fast staining and culture by
BACTEC 960 MGIT liquid culture media (BD) or Lo¨venstein
Jensen solid media. The patients diagnosed with active TB
were given standard anti-TB chemotherapy according to
national guidelines.33 Subjects with a positive QFT, but no
clinical signs or symptoms of active TB and no prior TB
that could explain QFT positivity, were defined as LTBI.
Blood samples were obtained before start of any anti-TB
chemotherapy and drawn into EDTA tubes. Plasma was
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80 C until analysis. Plasma samples from patients with
active TB were also obtained at 2e4 weeks, 6e12 weeks
and 12e24 weeks after the start of anti-TB chemotherapy.
Written informed consent was obtained from all partic-
ipants. The study was approved by the respective Regional
Committees for Ethics in Medical Research (REK-Vest, REK-
Nord and REK-Sør-øst).
QuantiFERON-TB Gold In-tube assay
The QuantiFERON TB-Gold In-tube assay was performed
according to the manufacturer’s instructions (Cellestis
Ltd, Qiagen, Chadstone, VIC, Australia) at the respective
hospitals. The cut-off value for positive test was
0.35 IU/ml.
Multiplex cytokine analysis
Plasma samples were analyzed using a multiplex cytokine
assay (Bio-Plex Human Cytokine 27-Plex Panel; Bio-Rad
Laboratories Inc., Hercules, CA) containing assays for
interleukin (IL)-1b, IL-1 receptor antagonist (IL-1ra), IL-2,
IL-4, IL-5, IL-6, IL-7, IL-8/CXCL8, IL-9, IL-10, IL-12(p70), IL-
13, IL-15, IL-17, basic fibroblast growth factor (bFGF),
granulocyte colony stimulating factor (G-CSF), granulocyte
macrophage colony stimulating factor (GM-CSF), IFN-g,
eotaxin/CCL11, IP-10/CXCL10, macrophage chemotattrac-
tant protein 1 (MCP-1)/CCL2, macrophage inflammatory
protein 1 alpha (MIP-1a)/CCL3, MIP-1b/CCL4, regulated on
activation, normal T cell expressed and secreted (RANTES)/
CCL5, tumor necrosis factor (TNF), platelet-derived growth
factor -BB (PDGF-BB) and vascular endothelial growth
factor (VEGF).
The samples were analyzed on a Multiplex Analyser using
Bio-Plex Manager 6.0 (Bio-Rad Laboratories) according to
the manufacturer’s instructions. Intra- and inter-assay
coefficients of variation were <12% for all analytes. Nine
of the markers evaluated (IL-1b, IL-2, IL-4, IL-5, IL-9, IL-10,
IL-13, IL-15 and GM-CSF) were below the lower detection
level (LDL) or detected at very low levels in all samples
(>80% below the LDL of the assay), and were therefore
excluded from further statistical analysis. The remaining
occasional values (<20%) below the LDL were replaced by a
defined common value below the LDL (0.001), which
allowed non-parametric statistical analysis.
Enzyme immunoassays (EIA)
Plasma levels of CXCL16, pentraxin 3 (PTX3), soluble TNF
receptor 2 (sTNFr2), Fas Ligand (FasL), thymus and activa-
tion regulated chemokine (TARC)/CCL17), osteoprotegerin
(OPG), activated leukocyte cell adhesion molecule (AL-
CAM), IL-23, secreted frizzled-related protein 3 (sFRP3) and
C-reactive protein (CRP) were measured by EIAs (R&D
Systems, Stillwater, MN). Intra-and inter-assay coefficients
of variation were <10% for all except FasL (<15%). MD-2
was analyzed by an in-house ELISA as previously
described.34 Briefly, MD-2 was captured on immune plates
coated with a TLR-4-Fc fusion protein and detected with di-
goxygenin labelled MD-2 mAb 5D7 or digoxigenin labelledIIC1 and anti-digoxygenin-HRP (Roche). The MD-2 standard
was purchased from R&D Systems, Stillwater, MN.
Statistical analysis
All statistical analyses were performed using IBM SPSS
statistics 21, Matlab 7.10. or GraphPad Prism 6. We initially
analyzed the HIV-infected and HIV-uninfected TB groups
separately using ManneWhitney U-test to detect pairwise
differences between the study subgroups at baseline. In
addition, we applied a binary logistic regression model to
evaluate whether each of the markers was able to differ-
entiate between active, LTBI and QFT negative controls
pairwise, when adjusted for age, sex and HIV-status.
ManneWhitney U-test was used to compare HIV-
uninfected MDR-Mtb vs. drug sensitive Mtb, and extrapul-
monary vs. pulmonary active TB cases, at time points where
the sample size in each of these groups were n  5. Wil-
coxon signed rank test was used to evaluate changes in
the levels of markers in patients with active TB from base-
line to each follow up time point during anti-TB chemo-
therapy. Spearman’s correlations were used to detect
relationships between the CD4 counts and selected markers
in the HIV-infected group.
The general significance level was set to 0.05. Taking
into account effects of multiple testing, the Bonferroni
adjustment would be too conservative due to the depen-
dence between the markers. Thus, we decided to use a
marginal significance level of 0.005 (corresponding to
Bonferroni adjustment for 10 tests), and to describe results
with p-values equal to or above 0.005 as significant and less
than 0.05 (0.005  p < 0.05) as tendencies.
Receiver operator characteristic (ROC) curve analyses
were performed for the most promising marker differenti-
ating between active and LTBI based on the results of the
aforementioned tests. The optimal cut-off levels were
defined by the minimum Euclidian distance to maximal
specificity and sensitivity.
Results
Study participant characteristics
A total of 164 study participants had plasma samples avail-
able for analysis and these were classified into three groups;
1) Active TB (n Z 65), 2) QFT-positive LTBI (n Z 34) and 3)
QFT negative controls (n Z 65). The patients were further
grouped according to HIV status. The clinical characteristics
of the study participants are summarized in Table 1. Six
(9.2%) of the patients with active TB, 23 (67.6%) of the indi-
viduals with LTBI and 52 (80.0%) of the QFT negative controls
were HIV-infected. A total of 51 (63%) of the HIV patients
were treated with antiretroviral therapy at inclusion in the
study. Two of the QFT negative HIV-infected controls had ac-
quired immune deficiency syndrome (AIDS)-defining infec-
tions (Herpes simplex virus, Mycobacterium avium
complex, Varicella zoster virus), with high HIV viral load
and CD4 counts below 100, but with no clinical signs of TB.
AIDS-defining infections were not seen in the LTBI group.
The active TB diagnosis was based on positive Mtb cul-
ture in 60 of the patients, whereas in five patients the
Table 1 Characteristics of the study participants.
Active TB (n Z 65) LTBI (QFT-positive, n Z 34) QFT-negative controls (n Z 65)
HIV-infected
(n Z 6)
HIV-uninfected
(n Z 59)
HIV-infected
(n Z 23)
HIV-uninfected
(n Z 11)
HIV-infected
(n Z 52)
HIV-uninfected
(n Z 13a)
Median age (range) 46 (38e64) 30 (16e91) 38 (21e48) 44 (24e61) 37 (19e68) 36 (26e70)
Sex: males/females 4/2 29/30 13/10 4/7 24/28 5/8
Origin: TB high/low
endemic country
5/1 52/7 23/0 8/3 34/18 1/12
Median CD4 count
(cells/mL, range)
286 (50e425) ND 475 (110e1870) ND 394 (3e1270) ND
HIV patients on
antiretroviral therapy (%)
4 (67) ND 9 (39) ND 38 (73) ND
TB localization: pulm./
extrapulm./disseminated
6/0/0 39/18/2
MDR-TB/mono-resistant TBb 1/1 10/4
Culture: positive/negative
or not performed
5/1 55/4
a 5 QFT-negative/HIV-uninfected controls were included in the Multiplex bead assay. 13 QFT-negative/HIV-uninfected controls were
included in the ELISA assays. ND: Not determined/relevant.
b Monoresistance against isoniazid, streptomycin or pyrazinamide.
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istic histopathological or radiological findings. There were
11 MDR-TB cases and two patients with disseminated TB
disease.
The patients with active TB had plasma samples ob-
tained at 2e4 weeks (nZ 24), at 6e12 weeks (nZ 24) and
at 12e24 weeks (n Z 20). Only two HIV-infected patients
with active TB had available plasma samples during treat-
ment, and these were therefore excluded from the statis-
tical analyses. All the patients with plasma samples
available during treatment were successfully treated,
except one patient who developed concomitant serious
disease with intestinal perforation and septicaemia leading
to death after 8 weeks of therapy. Thus, this patient was
excluded from the follow-up analyses.Impact of HIV infection on cytokine levels in
various stages of TB infection
We found significant higher levels of IP-10 and eotaxin
(p < 0.005) and a tendency of higher levels of FasL and
sTNFr2 (0.005  p < 0.05) in HIV co-infected compared with
HIV-uninfected active TB cases (Figs. 1 and 2). In contrast,
there was no significant impact of HIV infection on the
levels of any of the markers neither in subjects with LTBI
nor in QFT negative controls, although a tendency of
increased IP-10 and CXCL16 levels (0.005  p < 0.05)
were seen in the HIV-infected compared to the HIV-
uninfected LTBI group. Among QFT negative controls a ten-
dency of decreased level of MIP-1a, MIP-1b, sFRP3
(0.005  p < 0.05) and increased level of OPG
(0.005  p < 0.05) were observed in HIV-infected compared
with HIV-uninfected individuals.
We further analyzed whether there were any correla-
tions between the CD4 count and the level of IP-10 and
eotaxin, respectively, in the HIV-infected individuals. We
found a significant negative correlation between the CD4count and the level of IP-10 (p < 0.005, r Z 0.349)
(Fig. 3), but not with eotaxin (p Z 0.098, r Z 0.185).Cytokines differentiating between the various
stages of TB infection
Since we observed a significant impact of HIV co-infection
on the pattern of biomarkers in patients with active TB we
analyzed the HIV-infected and HIV-uninfected TB groups
separately.
In HIV-infected individuals there were significantly
higher levels of IP-10 and sTNFr2 in the active TB group
compared with both the LTBI group and QFT negative
controls (p < 0.005, Fig. 2), and there was a tendency of
PTX3, eotaxin and MCP-1 differentiating between active
and LTBI (0.005  p < 0.05). In contrast, in HIV-
uninfected individuals, PTX3 was the only marker that
significantly differentiated between active and LTBI
(p < 0.005, Fig. 2), but in addition IP-10, IL-8, VEGF, MD-2
and sFRP3 showed a tendency of differentiating
(0.005  p < 0.05). However, several markers significantly
distinguished (IL-8, PDGF-BB, TARC and CRP, p < 0.005) or
tended to distinguish (sFRP3, IL-7, eotaxin, OPG and
CXCL16, 0.005  p < 0.05) active TB from QFT negative
controls.
IP-10 and sTNFr2 also differentiated significantly
(p < 0.005) between active TB and both LTBI and QFT
negative controls when a binary logistic regression model
adjusting for HIV status, age and gender was applied. In
addition, in this model, PTX3 and CRP significantly differ-
entiated between active TB and QFT negative controls
(p < 0.005), and tended to differentiate between active TB
and LTBI (0.005  p < 0.05).
The diagnostic accuracy of IP-10 in differentiating be-
tween active TB, LTBI and the QFT negative control group
was investigated by ROC curve analyses (Table 2). In HIV-
infected individuals a cut-off level of 2547 pg/mL
Figure 1 Comparisons of cytokine levels between patients with active TB, latent TB and QFT-negative controls and between HIV-
infected and HIV-uninfected patients (ManneWhitney U test). Significant p-values (p < 0.005) are shown as a colour scale in green,
and p-values described as tendencies (0.005  p < 0.05) are shown as a colour scale ranging from red to black. ATB: active TB
infection. LTBI: Latent TB infection. QFT-: QuantiFERON-TB negative controls.
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Figure 2 Plasma levels of IP-10, sTNFr2, PTX3 and eotaxin in HIV-infected and HIV- uninfected patients with active TB, latent TB
and in QFT negative controls. The boxes show the median and interquartile range, and the whiskers show minimum and maximum
values. Statistical analysis was performed using the ManneWhitney U test. Brackets represent statistically significant differences
(p < 0.005).
386 I. Wergeland et al.discriminated active TB from LTBI with 100% sensitivity and
specificity, whereas in HIV-uninfected individuals the
optimal cut-off level was 689 pg/mL, and the sensitivities
and specificities were 71% and 82%, respectively.Changes in cytokine levels during anti-TB
chemotherapy
In HIV-uninfected patients with active TB, we analyzed the
levels of the various markers at different time-points
throughout therapy. The level of IP-10 decreased gradually
during treatment. There was a tendency of decrease
observed already after 6e12 weeks (p Z 0.022, Fig. 4).
However, the decrease was significant first after 12e24weeks (p Z 0.002), and the level was then comparable to
that seen both among the LTBI and in the QFT negative con-
trol group. By using the optimal cut-off level of 674 pg/mL
for differentiation between active TB and non-TB in HIV-
uninfected patients, 43/59 (73%) of the active TB patients
scored positive for plasma IP-10 at baseline, whereas 9/20
(45%) were positive at week 12e24. Only one patient with
extrapulmonary TB scored negative at baseline and became
positive during treatment. However, this patient had IP-10
levels close to cut-off both at baseline and during therapy.
sTNFr2 tended to decrease to the level of LTBI cases and
QFT negative controls after 12e24 weeks of treatment
(p Z 0.006), but in contrast to IP-10, which showed a uni-
form decrease over time, the level of sTNFr2 fluctuated
(Fig. 4).
Figure 3 Negative correlation between CD4 counts and
plasma IP-10 levels in HIV-infection. Spearman’s correlations
were used to detect relationships between the CD4 counts
and selected markers in the HIV-infected group. There was a
significant negative correlation between the CD4 count
(cells/mL) and the plasma level of IP-10 (pg/mL) in HIV infected
individuals (p < 0.005, r Z 0.349). ATB: active TB infection.
LTBI: Latent TB infection. QFT-: QuantiFERON-TB negative
controls.
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tiated between active TB and the LTBI and/or the QFT
negative control groups at baseline also declined
throughout therapy. PDGF-BB and TARC were significantly
decreased already after 2e4 weeks (p Z 0.002 and
p Z 0.004 respectively, Fig. 4), and there was a tendency
of decrease in CRP and IL-8, which reached the significance
level at week 12e24 (p Z 0.005, Fig. 4). PTX3, that signif-
icantly differentiated between active and LTBI at baseline,
did not decline during treatment. In contrast, a tendency of
increasing concentration of PTX3 was found after 6e12
weeks of treatment (p Z 0.042). However, when changes
in biomarker levels were analyzed in the Mtb sensitive
group separately, we found that the level of PTX3 tended
to decrease at week 6e12 (p Z 0.013), whereas there
was an increase in PTX3 for the majority of the MDR TB pa-
tients in the same period. For the other markers analyzed
we found no distinct differences in response patterns
when studying the drug sensitive Mtb cases separately
versus all active TB cases taken together.Table 2 ROC analyses with sensitivity and specificity of plasm
patients.
Cut-off
(pg/mL)
Sensitivity
HIV infected ATB vs. LTBI 2547 100 (54.1e
ATB vs. QFT negative 2532 100 (54.1e
HIV uninfected ATB vs. LTBI 689 71.2 (57.9e
ATB vs. QFT negative 674 72.9 (59.7e
ATB: Active TB infection. LTBI: Latent TB infection. QFT: QuantiFER
interval.There were also several markers which did not discrim-
inate significantly between the various study groups at
baseline, but where a significant decrease in concentra-
tions were observed in active TB cases during treatment;
RANTES (2e4 weeks), IL-1ra, IL-6, IL-12(p70), bFGF, IFN-g,
MIP-1a, TNF and VEGF (6e12 weeks), and G-CSF, MD-2 and
IL-7 (12e24 weeks), p < 0.005, Fig. 4).Discussion
In this study we have examined the potential of plasma
cytokines to differentiate between active and LTBI in HIV-
infected and HIV-uninfected individuals and longitudinal
changes in these markers during anti-TB chemotherapy. For
the first time we document that IP-10 and sTNFr2 can
differentiate active TB cases from both individuals with
LTBI and QFT negative controls irrespective of HIV status,
age and gender. Moreover, we found that the level of IP-10
in HIV-uninfected active TB cases decreased gradually to
the same level as LTBI and QFT negative controls after
12e24 weeks of anti-TB chemotherapy.
IP-10 is a chemokine produced by antigen presenting
cells mainly in response to IFN-g and TNF. It has been shown
that plasma levels of IP-10 are increased in bacteremia35
and infections with hepatitis C virus,36 HIV37,38 and
TB,14,25 and appear to correlate with the extent of inflam-
mation. In our study, the level of IP-10 was significantly
higher in HIV co-infected active TB cases compared with
HIV-uninfected cases. This is in concordance with a study
by Juffermans et al.,39 but in contrast, Mihret et al.14,27
and Riou et al.28 found no significant differences in the
level of IP-10 with respect to HIV-infection in patients
with active TB before anti-TB chemotherapy. We found a
significant negative correlation between the CD4 count
and the level of IP-10 in HIV-infected individuals supporting
studies of HIV-infected individuals without TB co-infec-
tion.37,40 The discordant results could therefore be due to
differences in CD4 counts between the HIV-infected groups
in the various studies.
IP-10 circulates at much higher levels compared to IFN-g
and has been extensively studied as an alternative to IFN-g
for immunodiagnosis of TB.16,17 In agreement with our re-
sults, it has been shown that plasma levels of IP-10 are
elevated in active TB cases compared with household con-
tacts.14,25,41 Our study is a valuable contribution to the
literature since HIV-infected subgroups are included both
in the active TB, the LTBI and the QFT negative groups,a IP-10 for tuberculosis in HIV-infected and HIV-uninfected
(95% CI) Specificity (95% CI) AUC (95% CI) p-value
100) 100 (85.2e100) 1.00 (1.00e1.00) <0.001
100) 92.3 (81.5e97.9) 0.96 (0.91e1.00) <0.001
82.2) 81.8 (48.2e97.7) 0.74 (0.59e0.89) 0.012
83.6) 60.0 (14.7e94.7) 0.66 (0.52e0.80) 0.235
ON-TB. AUC: Area under the ROC curve. 95% CI: 95% confidence
Figure 4 Plasma levels of selected soluble markers during anti-TB chemotherapy; IP-10, sTNFr2, CRP, PDGF-BB, IFN-g and TNF-a
in HIV-uninfected patients with active TB before and after 2e4, 6e12 and 12e24 weeks compared to the HIV-uninfected LTBI and
QFT-negative groups. Changes in the plasma level of markers from baseline to each follow up time point during treatment were
analyzed using Wilcoxon matched pairs signed rank test. Brackets represent statistically significant differences (p < 0.005).
ATB: active TB infection. LTBI: Latent TB infection. QFT-: QuantiFERON-TB negative controls. BL: baseline.
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guish active TB from LTBI and QFT negative controls irre-
spective of HIV co-infection. The ROC curve analyses
show that plasma IP-10 with a cut of 2547 pg/mL clearly dif-
ferentiates between active TB and LTBI in HIV-infected in-
dividuals with 100% sensitivity and specificity. In HIV-
uninfected individuals the diagnostic accuracy was less
optimal and the cut-off level was 689 pg/mL which is
notably higher than reported by Hong et al. (119.5 pg/
mL).41 This discrepancy is most likely explained by differ-
ences in methods of detection and variations in study pop-
ulations, and emphasizes the importance of determining
validated cut-offs before IP-10 can be used in clinical
practice.
Our results support previous studies demonstrating a
decrease in plasma level of IP-10 upon anti-TB chemo-
therapy of HIV-uninfected active TB cases,14,25e28 whereas
there are conflicting results in HIV co-infected cases. Riouet al. reported that IP-10 decreased irrespective of HIV
infection,28 but Mihret et al. documented a decline only
for HIV-uninfected cases.27 In a study by Azzuri et al., IP-
10 increased in household contacts during progression to
active TB and during relapse of TB in patients who previ-
ously had completed anti-TB chemotherapy.25 Patients
with active TB with moderate to high risk of relapse decline
less in IP-10 during treatment compared with low risk pa-
tients.26 It has also been suggested that serial determina-
tions of serum IP-10 can be used to identify individuals
with rheumatoid arthritis at high risk of developing active
TB during TNF inhibitor treatment.42 Further, plasma level
of IP-10 correlates with the sputum smear acid fast bacilli
grade26,43 and the degree of lung involvement.25 Although
there was a tendency of decline already at 6e12 weeks,
we found defined by our definition of significance level, a
decrease in the level of IP-10 first after 12e24 weeks of
treatment. We report a reduction in the fraction of active
IP-10 as biomarker in tuberculosis 389TB patients with positive plasma IP-10 from 73% at baseline
to 45% during anti-TB chemotherapy in line with a previous
report.26 Other markers, including PDGF-BB, TARC and IFN-
g showed an earlier significant decrease in response to
therapy compared with IP-10, but these markers were not
able to differentiate between the various stages of TB
infection.
IP-10 measured directly in plasma is unspecific for TB,
but IP-10 has also been studied as a potential readout
biomarker in in vitro Mtb specific immunoassays. A review
by Ruhwald et al. concludes that IP-10 release assays
perform comparably to the QFT-test in most patient groups,
but may improve the diagnostic accuracy in children and in
HIV-infected individuals with low CD4 counts.17 However,
the Mtb specific immunoassays does not seem to be able
to differentiate between active and LTBI,3,17 and IGRAs
cannot be used for monitoring treatment.5 Hong et al.
found that IP-10 secretion in response to QFT antigens
decreased during anti-TB chemotherapy,26 whereas Kabeer
et al. could not confirm this, but rather detected decrease
in response to RD1-selected peptides.29
The relatively high level of plasma IP-10 compared with
other biomarkers, allows for simplification of analyzes.
Methods for quantification of IP-10 in dried blood and
plasma spots (DBS/DPS) have been developed, facilitating
point-of-care tests and transport of samples at ambient
temperatures.44e46 DPS/DBS-based IP-10 release assays
offer comparable diagnostic accuracy to the QFT.44,47 IP-
10, in contrast to IFN-g and TNF-a, could also be detected
in urine from TB patients and pulmonary TB patients have
significantly higher urine IP-10 levels than healthy con-
trols.48 Moreover, the urine IP-10 level in cured TB patients
were comparable to that found in healthy controls.48 Urine
samples have several advantaged including non-invasive
collection, low cost and no need of special equipment or
personnel. Still, care most be taken when detecting IP-10
in urine, as high urine IP-10 levels are also associated
with chronic hepatitis C virus infection.49 Thus, further
studies are needed to determine whether urine IP-10 is a
reliable alternative to plasma IP-10.
sTNFr2 can act as a TNF antagonist by competing with
the cell membrane receptors for cytokine binding. It is the
biologically active component of the TNF inhibitor etaner-
cept, which, among other TNF inhibitors, has been associ-
ated with increased risk of reactivation of latent TB
infection.50 Elevated levels of TNF have been found in
patients with active TB compared with household contacts
and healthy controls.51 Further, Jufferman et al. found that
both sTNFr1 and sTNFr2 are increased in active TB cases
and decline during treatment.52 In our study, although
finally declined, the level fluctuated during treatment.
Riou et al. show that the level of TNF also fluctuates during
treatment.28 We found a gradual decrease in the level of
TNF, which was significant after 6e12 weeks of therapy.
However, since there were no significant differences in
TNF level between any of our study groups at baseline
this questions the usefulness as biomarker for therapy effi-
cacy. Finally, if sTNFr2 may serve as a reliable marker of
TNF activity is also unknown.
The pentraxin family, including CRP and PTX3, is
involved in the acute phase reaction to inflammation.53
PTX3 was the only marker that significantly differentiatedbetween active and LTBI when HIV-uninfected individuals
were studied separately, and also showed a tendency of
differentiating between these groups in HIV-infected indi-
viduals. Azzuri et al. found that the plasma level of PTX3
was higher in patients with active TB compared with
healthy household controls, decreased with successful
treatment and increased in patients with treatment fail-
ure.25 When patients with MDR-TB and drug sensitive Mtb
were analyzed as one group we found a tendency of in-
crease in the level of PTX3 during treatment. However,
when analyzed separately, PTX3 tended to decrease in
the drug sensitive Mtb group whereas there was an initial
increase, followed by a decline after 24e48 months in
MDR TB patients (data not shown). This may indicate that
there is a delayed response to treatment in MDR compared
with drug sensitive Mtb. CRP, which is extensively used as a
marker of inflammation, declined steadily, but only near
significantly, during treatment.
The main limitations of our study are the low sample size
of HIV-infected patients with active TB and the lack of
longitudinal follow up plasma samples from this group
during treatment. This was included in the design of the
original study,31 but there was a low prevalence of active
TB in the HIV-infected population, and only two HIV-
infected patients had plasma samples obtained during
treatment. Also, the changes in markers during treatment
of active TB were assessed together regardless of drug
resistant or sensitive Mtb, although the treatment differed
in composition of antibiotics and length. We found indica-
tions that the kinetics of some of the biomarkers may differ
between MDR and drug sensitive Mtb. Still, the majority of
patients had Mtb sensitive strains, received standard anti-
TB chemotherapy and all patients responded to treatment.
Finally, since plasma IP-10 is unspecific for TB, our study
should also have included patients with diagnoses other
than TB, including AIDS-defining infections, to optimally
validate the accuracy of the method. The two HIV patients
in the QFT negative control group with other opportunistic
infections clearly demonstrate this since they had plasma
IP-10 levels above the median level of the HIV-infected
active TB group. Still, our study was not designed to fully
validate IP-10, but we recommend awareness of infections
other than TB in the interpretation of plasma levels of IP-
10, particularly in patients with HIV-confection.
In conclusion, IP-10 appears to be the most consistent of
the biomarkers studied as it was the only marker that
significantly differentiated active TB from both LTBI and
QFT negative controls irrespective of HIV status, and also
significantly declined during anti-TB chemotherapy of HIV-
uninfected active TB cases. Although not specific for TB,
plasma level of IP-10 may give information about the stage
of infection, and may also be used to monitor the effect of
treatment, but further studies are needed to validate and
standardize IP-10 assays.Acknowledgements
We wish to thank the staff at the research laboratories at
the Dep. of Infectious Diseases, Oslo University Hospital and
Haukeland University Hospital for contributing to inclusion
of patients and processing of samples, especially Mette
390 I. Wergeland et al.Sannes, Helene Gjelsas and Christel Gill Haanshuus. The
study was funded by grants from the Norwegian Extra-
Foundation for Health and Rehabilitation (2008-2-0159),
The North Norway Regional Health Authority (SFP890-09)
and the “Blakstad and Maarschalk Tuberkulosefond”. The
funding sources were not involved in design of the study, in-
terpitation of data or in writing of the manuscript.
References
1. World Health Organization. Global tuberculosis report.
2014. Available: http://www.who.int/tb/publications/
global_report/en/ [accessed 12.12.14].
2. Selwyn PA, Hartel D, Lewis VA, Schoenbaum EE, Vermund SH,
Klein RS, et al. A prospective study of the risk of tuberculosis
among intravenous drug users with human immunodeficiency
virus infection. N Engl J Med 1989 Mar 2;320(9):545e50.
3. Pai M, Denkinger CM, Kik SV, Rangaka MX, Zwerling A,
Oxlade O, et al. Gamma interferon release assays for detec-
tion of Mycobacterium tuberculosis infection. Clin Microbiol
Rev 2014 Jan;27(1):3e20.
4. Parida SK, Kaufmann SH. The quest for biomarkers in tubercu-
losis. Drug Discov Today 2010 Feb;15(3e4):148e57.
5. Chiappini E, Fossi F, Bonsignori F, Sollai S, Galli L, de MM. Util-
ity of interferon-gamma release assay results to monitor anti-
tubercular treatment in adults and children. Clin Ther 2012
May;34(5):1041e8.
6. Holtz TH, Sternberg M, Kammerer S, Laserson KF, Riekstina V,
Zarovska E, et al. Time to sputum culture conversion in
multidrug-resistant tuberculosis: predictors and relationship
to treatment outcome. Ann Intern Med 2006 May 2;144(9):
650e9.
7. Wallis RS, Wang C, Doherty TM, Onyebujoh P, Vahedi M,
Laang H, et al. Biomarkers for tuberculosis disease activity,
cure, and relapse. Lancet Infect Dis 2010 Feb;10(2):68e9.
8. Benator D, Bhattacharya M, Bozeman L, Burman W,
Cantazaro A, Chaisson R, et al. Rifapentine and isoniazid
once a week versus rifampicin and isoniazid twice a week
for treatment of drug-susceptible pulmonary tuberculosis in
HIV-negative patients: a randomised clinical trial. Lancet
2002 Aug 17;360(9332):528e34.
9. Johnson JL, Hadad DJ, Dietze R, Maciel EL, Sewali B, Gitta P,
et al. Shortening treatment in adults with noncavitary tuber-
culosis and 2-month culture conversion. Am J Respir Crit Care
Med 2009 Sep 15;180(6):558e63.
10. Biselli R, Mariotti S, Sargentini V, Sauzullo I, Lastilla M,
Mengoni F, et al. Detection of interleukin-2 in addition to
interferon-gamma discriminates active tuberculosis patients,
latently infected individuals, and controls. Clin Microbiol
Infect 2010 Aug;16(8):1282e4.
11. Chegou NN, Black GF, Kidd M, van Helden PD, Walzl G. Host
markers in QuantiFERON supernatants differentiate active
TB from latent TB infection: preliminary report. BMC Pulm
Med 2009;9:21.
12. Chegou NN, Detjen AK, Thiart L, Walters E, Mandalakas AM,
Hesseling AC, et al. Utility of host markers detected in Quan-
tiferon supernatants for the diagnosis of tuberculosis in chil-
dren in a high-burden setting. PLoS One 2013;8(5):e64226.
13. Frahm M, Goswami ND, Owzar K, Hecker E, Mosher A,
Cadogan E, et al. Discriminating between latent and active
tuberculosis with multiple biomarker responses. Tuberculosis
(Edinb ) 2011 May;91(3):250e6.
14. Mihret A, Bekele Y, Bobosha K, Kidd M, Aseffa A, Howe R,
et al. Plasma cytokines and chemokines differentiate be-
tween active disease and non-active tuberculosis infection.
J Infect 2013 Apr;66(4):357e65.15. Sutherland JS, de Jong BC, Jeffries DJ, Adetifa IM, Ota MO.
Production of TNF-alpha, IL-12(p40) and IL-17 can discrimi-
nate between active TB disease and latent infection in a
West African cohort. PLoS One 2010;5(8):e12365.
16. Chegou NN, Heyckendorf J, Walzl G, Lange C, Ruhwald M.
Beyond the IFN-gamma horizon: biomarkers for immunodiag-
nosis of infection with M. tuberculosis. Eur Respir J 2014
May;43(5):1472e86.
17. Ruhwald M, Aabye MG, Ravn P. IP-10 release assays in the
diagnosis of tuberculosis infection: current status and future
directions. Expert Rev Mol Diagn 2012 Mar;12(2):175e87.
18. Goletti D, Raja A, Syed Ahamed KB, Rodrigues C, Sodha A,
Carrara S, et al. Is IP-10 an accurate marker for detecting
M. tuberculosis-specific response in HIV-infected persons?
PLoS One 2010;5(9):e12577.
19. Kabeer BS, Sikhamani R, Raja A. Comparison of interferon
gamma and interferon gamma-inducible protein-10 secretion
in HIV-tuberculosis patients. AIDS 2010 Jan 16;24(2):323e5.
20. Vanini V, Petruccioli E, Gioia C, Cuzzi G, Orchi N, Rianda A,
et al. IP-10 is an additional marker for tuberculosis (TB)
detection in HIV-infected persons in a low-TB endemic coun-
try. J Infect 2012 Jul;65(1):49e59.
21. Alsleben N, Ruhwald M, Russmann H, Marx FM, Wahn U,
Magdorf K. Interferon-gamma inducible protein 10 as a
biomarker for active tuberculosis and latent tuberculosis
infection in children: a case-control study. Scand J Infect
Dis 2012 Apr;44(4):256e62.
22. Latorre I, Diaz J, Mialdea I, Serra-Vidal M, Altet N, Prat C,
et al. IP-10 is an accurate biomarker for the diagnosis of
tuberculosis in children. J Infect 2014 Dec;69(6):590e9.
23. Lighter J, Rigaud M, Huie M, Peng CH, Pollack H. Chemokine
IP-10: an adjunct marker for latent tuberculosis infection in
children. Int J Tuberc Lung Dis 2009 Jun;13(6):731e6.
24. Ruhwald M, Petersen J, Kofoed K, Nakaoka H, Cuevas LE,
Lawson L, et al. Improving T-cell assays for the diagnosis of
latent TB infection: potential of a diagnostic test based on
IP-10. PLoS One 2008;3(8):e2858.
25. Azzurri A, Sow OY, Amedei A, Bah B, Diallo S, Peri G, et al.
IFN-gamma-inducible protein 10 and pentraxin 3 plasma
levels are tools for monitoring inflammation and disease ac-
tivity in Mycobacterium tuberculosis infection. Microbes
Infect 2005 Jan;7(1):1e8.
26. Hong JY, Lee HJ, Kim SY, Chung KS, Kim EY, Jung JY, et al. Ef-
ficacy of IP-10 as a biomarker for monitoring tuberculosis
treatment. J Infect 2014 Mar;68(3):252e8.
27. Mihret A, Abebe M, Bekele Y, Aseffa A, Walzl G, Howe R.
Impact of HIV co-infection on plasma level of cytokines and
chemokines of pulmonary tuberculosis patients. BMC Infect
Dis 2014;14:125.
28. Riou C, Perez PB, Roberts L, Ronacher K, Walzl G, Manca C,
et al. Effect of standard tuberculosis treatment on plasma
cytokine levels in patients with active pulmonary tubercu-
losis. PLoS One 2012;7(5):e36886.
29. Kabeer BS, Raja A, Raman B, Thangaraj S, Leportier M,
Ippolito G, et al. IP-10 response to RD1 antigens might be a
useful biomarker for monitoring tuberculosis therapy. BMC
Infect Dis 2011;11:135.
30. Dyrhol-Riise AM, Gran G, Wentzel-Larsen T, Blomberg B,
Haanshuus CG, Morkve O. Diagnosis and follow-up of treat-
ment of latent tuberculosis; the utility of the QuantiFERON-
TB Gold In-tube assay in outpatients from a tuberculosis
low-endemic country. BMC Infect Dis 2010;10:57.
31. Pullar ND, Steinum H, Tonby K, Heggelund L, Leiva RA,
Ofstad R, et al. Low prevalence of positive interferon-
gamma tests in HIV-positive long-term immigrants in Norway.
Int J Tuberc Lung Dis 2014 Feb;18(2):180e7.
32. Feruglio SL, Tonby K, Kvale D, Dyrhol-Riise AM. Early dynamics
of T helper cell cytokines and T regulatory cells in response to
IP-10 as biomarker in tuberculosis 391treatment of active Mycobacterium tuberculosis infection.
Clin Exp Immunol 2014 Oct 14.
33. Nasjonalt folkehelseinstitutt. Tuberkuloseveilederen (Norwe-
gian, Guidelines for tuberculosis). 2014. Available: http://
www.fhi.no/publikasjoner-og-haandboker/tuberkuloseveile
deren [accessed 23.05.14].
34. Sandanger O, Ryan L, Bohnhorst J, Iversen AC, Husebye H,
Halaas O, et al. IL-10 enhances MD-2 and CD14 expression in
monocytes and the proteins are increased and correlated in
HIV-infected patients. J Immunol 2009 Jan 1;182(1):588e95.
35. Punyadeera C, Schneider EM, Schaffer D, Hsu HY, Joos TO,
Kriebel F, et al. A biomarker panel to discriminate between
systemic inflammatory response syndrome and sepsis and
sepsis severity. J Emerg Trauma Shock 2010 Jan;3(1):26e35.
36. Askarieh G, Alsio A, Pugnale P, Negro F, Ferrari C, Neumann AU,
et al. Systemic and intrahepatic interferon-gamma-inducible
protein 10 kDa predicts the first-phase decline in hepatitis C vi-
rus RNA and overall viral response to therapy in chronic hepati-
tis C. Hepatology 2010 May;51(5):1523e30.
37. Keating SM, Golub ET, Nowicki M, Young M, Anastos K,
Crystal H, et al. The effect of HIV infection and HAART on in-
flammatory biomarkers in a population-based cohort of
women. AIDS 2011 Sep 24;25(15):1823e32.
38. Stylianou E, Aukrust P, Bendtzen K, Muller F, Froland SS. Inter-
ferons and interferon (IFN)-inducible protein 10 during highly
active anti-retroviral therapy (HAART)-possible immunosup-
pressive role of IFN-alpha in HIV infection. Clin Exp Immunol
2000 Mar;119(3):479e85.
39. Juffermans NP, Verbon A, van Deventer SJ, van DH, Belisle JT,
Ellis ME, et al. Elevated chemokine concentrations in sera of
human immunodeficiency virus (HIV)-seropositive and HIV-
seronegative patients with tuberculosis: a possible role for
mycobacterial lipoarabinomannan. Infect Immun 1999 Aug;
67(8):4295e7.
40. Liovat AS, Rey-Cuille MA, Lecuroux C, Jacquelin B, Girault I,
Petitjean G, et al. Acute plasma biomarkers of T cell activa-
tion set-point levels and of disease progression in HIV-1 infec-
tion. PLoS One 2012;7(10):e46143.
41. Hong JY, Jung GS, Kim H, Kim YM, Lee HJ, Cho SN, et al. Effi-
cacy of inducible protein 10 as a biomarker for the diagnosis
of tuberculosis. Int J Infect Dis 2012 Dec;16(12):e855e9.
42. Chen DY, Shen GH, Chen YM, Chen HH, Lin CC, Hsieh CW,
et al. Interferon-inducible protein-10 as a marker to detectlatent and active tuberculosis in rheumatoid arthritis. Int J
Tuberc Lung Dis 2011 Feb;15(2):192e200.
43. Chen YC, Chin CH, Liu SF, Wu CC, Tsen CC, Wang YH, et al.
Prognostic values of serum IP-10 and IL-17 in patients with
pulmonary tuberculosis. Dis Markers 2011;31(2):101e10.
44. Blauenfeldt T, Heyckendorf J, Graff JS, Lange C, Drabe C,
Hermansen TS, et al. Development of a one-step probe based
molecular assay for rapid immunodiagnosis of infection with
M. tuberculosis using dried blood spots. PLoS One 2014;9(9):
e105628.
45. Drabe CH, Blauenfeldt T, Ruhwald M. ELISA-based assay for IP-
10 detection from filter paper samples. Methods Mol Biol
2014;1172:27e37.
46. Aabye MG, Eugen-Olsen J, Werlinrud AM, Holm LL,
Tuuminen T, Ravn P, et al. A simple method to quantitate
IP-10 in dried blood and plasma spots. PLoS One 2012;7(6):
e39228.
47. Aabye MG, Latorre I, Diaz J, Maldonado J, Mialdea I, Eugen-
Olsen J, et al. Dried plasma spots in the diagnosis of tubercu-
losis: IP-10 release assay on filter paper. Eur Respir J 2013
Aug;42(2):495e503.
48. Cannas A, Calvo L, Chiacchio T, Cuzzi G, Vanini V, Lauria FN,
et al. IP-10 detection in urine is associated with lung diseases.
BMC Infect Dis 2010;10:333.
49. Petrone L, Chiacchio T, Vanini V, Petruccioli E, Cuzzi G, Di GC,
et al. High urine IP-10 levels associate with chronic HCV infec-
tion. J Infect 2014 Jun;68(6):591e600.
50. Wallis RS. Tumour necrosis factor antagonists: structure,
function, and tuberculosis risks. Lancet Infect Dis 2008 Oct;
8(10):601e11.
51. Wang S, Diao N, Lu C, Wu J, Gao Y, Chen J, et al. Evaluation of
the diagnostic potential of IP-10 and IL-2 as biomarkers for
the diagnosis of active and latent tuberculosis in a BCG-
vaccinated population. PLoS One 2012;7(12):e51338.
52. Juffermans NP, Verbon A, van Deventer SJ, van DH,
Speelman P, van der Poll T. Tumor necrosis factor and
interleukin-1 inhibitors as markers of disease activity of
tuberculosis. Am J Respir Crit Care Med 1998 Apr;157(4 Pt
1):1328e31.
53. Mantovani A, Garlanda C, Bottazzi B. Pentraxin 3, a non-
redundant soluble pattern recognition receptor involved in
innate immunity. Vaccine 2003 Jun 1;21(Suppl. 2):S43e7.
